Bronchitis can be caused by any virus or bacteria, although viral bronchitis is much more common. Bronchitis is an inflammation of the lining of the bronchial tubes, which carry air to and from the lungs. Bronchitis might be either acute or chronic. Often developing from a cold or other respiratory infection, acute bronchitis is very common. Chronic bronchitis, however, is a serious condition. It is a constant irritation or inflammation of the lining of the bronchial tubes. This occurs mostly due to smoking. The major risk factors for bronchitis include smoking, low immune resistance, gastric reflux, and others.
Pneumonia is a common complication of bronchitis. It occurs when the infection spreads much further into the lungs, which causes the tiny air sacs inside the lungs to fill up with fluid. It is estimated that nearly 1 in 20 cases of bronchitis lead to pneumonia. According to the CDC, in 2016, more than 8.9 million Americans were diagnosed with chronic bronchitis, and this number is expected to increase further in the coming years
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence